Nonclassical signaling of the androgen receptor polyproline domain
Nonclassical signaling of the androgen receptor polyproline domain
批准号:
8142842
负责人:
Daniel Edward Frigo
金额:
$13.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2013-06-30
关键词:
Academic Medical CentersActinsAndrogen ReceptorAndrogensBindingBioinformaticsBiologicalBiological AssayBiological ProcessBiologyCancer BiologyCellsComplementDataDevelopmentEmerging TechnologiesEndocrineEnvironmentFutureGene TargetingGeneticGenomeGenomicsGoalsGrowthHealthIn VitroInstitutesInterventionLigandsLinkMediatingModificationMolecular BiologyMolecular ConformationMutationNatureNuclear ReceptorsOutcomePharmacologic SubstancePharmacologyPhosphotransferasesProcessProlineProteinsPublishingRecruitment ActivityRegulationResearchRoleScience PolicySignal PathwaySignal TransductionStretchingStudy SectionSurfaceTestingTissuesWorkbasecareercofactorcomputerized toolsdesigninsightknowledge basemigrationnovelnovel therapeutic interventionpolyprolinereceptorselective androgen receptor modulator
中文摘要
描述(由申请人提供):
已经确定,核受体的整体构象受它们所结合的配体的性质影响,并且所产生的构象差异使得辅因子的差异募集成为可能。尽管有这些公认的概念,但仍有待确定(a)哪些受体表面负责每种生物活性和(B)这些表面如何机械地起作用。我已经确定了一个这样的表面,即位于AR N末端的一段独特的脯氨酸残基,这对于最大化AR介导的生长和选择雄激素靶基因的调节是必要的。
候选人的长期目标是为内分泌疾病开发新的治疗方法。该提案的主要目标是使用生物信息学和分子生物学的组合来定义AR聚脯氨酸结构域和与该特定表面相互作用的两种鉴定的蛋白质的特定作用。这些目标将利用杜克大学医学中心药理学和癌症生物学系以及杜克基因组科学和政策研究所的一流研究环境来实现。为实现这些目标,提出了以下具体目标:
目的1:确定雄激素受体内多聚脯氨酸结构域在雄激素调节的生物学过程中的作用。
目标二:识别和验证由AR及其聚脯氨酸结构域引发的特定信号通路,这些信号通路驱动细胞效应,如生长,迁移和肌动蛋白重组。
目标3:评价AR聚脯氨酸结构域及其辅因子SH 3 YL 1和林恩激酶的遗传修饰对选择性雄激素受体调节剂(SARM)活性的影响。
这项工作将提供一个明确的评估的作用,多聚脯氨酸结构域在AR生物学和推进我们的基本了解AR信号。从这项工作的见解将促进机制为基础的屏幕开发的化合物,SARMs,有用的组织选择性活动。
公共卫生相关性:预计该项目将有助于开发可以选择性调节雄激素调节作用的药理学策略所需的知识基础。在这些研究的结论中,我们将能够直接将特定的生物过程与特定的AR-辅因子相互作用联系起来。这些新的信息将是非常宝贵的AR配体的未来设计。
英文摘要
DESCRIPTION (provided by applicant):
It has been determined that the overall conformation of nuclear receptors is influenced by the nature of the ligand to which they bind and that the resulting differences in conformation enable the differential recruitment of cofactors. Despite these accepted concepts, it still remains to be determined (a) which receptor surfaces are responsible for each biological activity and (b) how these surfaces function mechanistically. I have identified one such surface, a unique stretch of proline residues located towards the N-terminus of AR, that is necessary for maximal AR-mediated growth and the regulation of select androgen target genes.
The long-term goal of the candidate is to develop novel therapeutic approaches for endocrine maladies. The primary goal of this proposal is to use a combination of bioinformatics and molecular biology to define the specific role(s) of the AR polyproline domain and two identified proteins that interact with this specific surface. These goals will be achieved using the superb research environment at Duke University Medical Center within both the Department of Pharmacology and Cancer Biology and the Duke Institute of Genome Sciences and Policy. To accomplish these goals the following specific aims are proposed:
Aim 1: Determine the role of the polyproline domain within AR in androgen-regulated biological processes.
Aim 2: Identify and validate the specific signaling pathways elicited by AR and its polyproline domain that drive cellular effects such as growth, migration, and actin reorganization.
Aim 3: Evaluate the impact of genetic modification of the AR polyproline domain and its cofactors, SH3YL1 and Lyn kinase, on the activity of selective androgen receptor modulators (SARMs).
This work will provide a definitive assessment of the role of the polyproline domain in AR biology and advance our basic understanding of AR signaling. Insights from this work will facilitate mechanism-based screens for the development of compounds, SARMs, with useful tissue-selective activities.
PUBLIC HEALTH RELEVANCE: It is anticipated this project will contribute to the knowledge base needed to develop pharmacological strategies that can selectively modulate androgen-regulated actions. At the conclusion of these studies we will be able to directly link a specific biological process to a particular AR-cofactor interaction. This new information will be invaluable for the future design of AR ligands.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Revisiting Antiangiogenic Therapy to Target Hormone-Sensitive Prostate Cancer Metabolism
-
批准号:10671250
-
项目类别:
-
资助金额:$56.69万
-
财政年份:2023
-
负责人:Daniel Edward Frigo
-
依托单位:
Delineation of the Role of CAMKK2 in Bone-metastatic Prostate Cancer and its Therapeutic Implications
-
批准号:10593983
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2022
-
负责人:Daniel Edward Frigo
-
依托单位:
Delineation of the Role of CAMKK2 in Bone-metastatic Prostate Cancer and its Therapeutic Implications
-
批准号:10435266
-
项目类别:
-
资助金额:$9.58万
-
财政年份:2022
-
负责人:Daniel Edward Frigo
-
依托单位:
FASEB's "The Steroid Hormones and Receptors in Health and Disease Conference - Jointly hosted by FASEB and the International Committee on Rapid Responses to Steroid Hormones (RRSH)"
-
批准号:10063235
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2020
-
负责人:Daniel Edward Frigo
-
依托单位:
Genetic & Metabolic Dissection of the CaMKKbeta Signaling Axis in Prostate Cancer
-
批准号:8818191
-
项目类别:
-
资助金额:$36.2万
-
财政年份:2015
-
负责人:Daniel Edward Frigo
-
依托单位:
Genetic & Metabolic Dissection of the CaMKKbeta Signaling Axis in Prostate Cancer
-
批准号:9179334
-
项目类别:
-
资助金额:$5.44万
-
财政年份:2015
-
负责人:Daniel Edward Frigo
-
依托单位:
Androgen Receptor- and Myc-Mediated Glutamine Metabolism in Prostate Cancer
-
批准号:8809478
-
项目类别:
-
资助金额:$20.25万
-
财政年份:2015
-
负责人:Daniel Edward Frigo
-
依托单位:
Genetic & Metabolic Dissection of the CaMKKbeta Signaling Axis in Prostate Cancer
-
批准号:9207070
-
项目类别:
-
资助金额:$34.98万
-
财政年份:2015
-
负责人:Daniel Edward Frigo
-
依托单位:
Genetic & Metabolic Dissection of the CaMKKbeta Signaling Axis in Prostate Cancer
-
批准号:9000138
-
项目类别:
-
资助金额:$34.98万
-
财政年份:2015
-
负责人:Daniel Edward Frigo
-
依托单位:
Androgen Receptor- and Myc-Mediated Glutamine Metabolism in Prostate Cancer
-
批准号:8997483
-
项目类别:
-
资助金额:$16.98万
-
财政年份:2015
-
负责人:Daniel Edward Frigo
-
依托单位:
Modulation of Branched-Chain Fatty Acids for the Prevention of Prostate Cancer
-
批准号:8469411
-
项目类别:
-
资助金额:$7.05万
-
财政年份:2012
-
负责人:Daniel Edward Frigo
-
依托单位:
Modulation of Branched-Chain Fatty Acids for the Prevention of Prostate Cancer
-
批准号:8236244
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2012
-
负责人:Daniel Edward Frigo
-
依托单位:
Androgenic Regulation of Autophagy in the Prostate
-
批准号:8269891
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2011
-
负责人:Daniel Edward Frigo
-
依托单位:
Androgenic Regulation of Autophagy in the Prostate
-
批准号:8174574
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2011
-
负责人:Daniel Edward Frigo
-
依托单位:
Nonclassical signaling of the androgen receptor polyproline domain
-
批准号:7708419
-
项目类别:
-
资助金额:$10.55万
-
财政年份:2009
-
负责人:Daniel Edward Frigo
-
依托单位:
Nonclassical signaling of the androgen receptor polyproline domain
-
批准号:7920248
-
项目类别:
-
资助金额:$13.88万
-
财政年份:2009
-
负责人:Daniel Edward Frigo
-
依托单位:
Estrogen Receptor Beta Pharmacology in the Prostate
-
批准号:7256950
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2005
-
负责人:Daniel Edward Frigo
-
依托单位:
Estrogen Receptor Beta Pharmacology in the Prostate
-
批准号:7095899
-
项目类别:
-
资助金额:$4.88万
-
财政年份:2005
-
负责人:Daniel Edward Frigo
-
依托单位:
Estrogen Receptor Beta Pharmacology in the Prostate
-
批准号:6994972
-
项目类别:
-
资助金额:$4.4万
-
财政年份:2005
-
负责人:Daniel Edward Frigo
-
依托单位:
海外基金